Mabqi has been selected to join the Paris Saclay Cancer Cluster (PSCC) BOOST Programme, an initiative designed to accelerate the development of innovative oncology companies.
Through this program, Mabqi will benefit from tailored, high-level scientific and medical support, access to a unique ecosystem of experts, leading hospitals, industry partners, and investors, as well as critical resources including data, platforms, and infrastructure.
This comprehensive support will help accelerate the advancement of one of our lead assets toward clinical development.
“We are deeply honored to have been selected alongside other leading oncology innovators,” said Sylvain Yon, CEO. “The BOOST programme will provide cutting-edge scientific and technical expertise, significantly accelerating the development of our lead asset—a first-in-class immunotherapy with a novel mechanism of action and broad pan-cancer potential.”
We would like to extend our sincere thanks to our team, our partners, and the PSCC for their trust and support.
